Researchers have identified a distinct subtype of Sjögren disease driven by elevated interferon alfa levels — and the warning signs can appear over a decade before diagnosis. A five-protein blood signature called SIRO detected IFN-related changes up to 14 years before patients were diagnosed. Mouse models confirmed the link, though blocking IFN signaling only partially reversed the immune abnormalities.
Scientists have uncovered a distinct subtype of Sjögren disease — a chronic autoimmune condition — defined by elevated levels of interferon (IFN) alfa, a key immune signaling protein. Published in The Lancet Rheumatology, the study found that about 61% of Sjögren patients had elevated IFN alfa levels, which strongly correlated with abnormal immune cell counts, higher antibody levels, and more autoantibodies compared to those without elevated levels.
Perhaps most strikingly, the researchers developed a five-protein blood test called SIRO (Sjögren IFN Alfa Response in Olink) that could detect IFN-related immune changes up to 14 years before a Sjögren diagnosis — offering a potential window for early intervention. Engineered mice that overproduced IFN alfa mirrored the human disease features, though blocking the IFN receptor only partially reversed the immune changes, suggesting the pathway is necessary but not sufficient on its own.
Key Takeaways:
Why it matters: Early detection of Sjögren disease has long been a challenge, as diagnosis often comes years after symptoms begin. This research suggests that a simple blood protein signature could one day help clinicians identify at-risk patients far earlier and tailor treatments to specific disease subtypes.
